Drug Profile
Research programme: cardiovascular disease gene therapy - Boehringer Ingelheim/Inovio
Alternative Names: Cardiovascular disease gene therapy - Boehringer Ingelheim/InovioLatest Information Update: 18 Aug 2009
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Inovio Biomedical Corporation
- Class Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 18 Aug 2009 Discontinued - Preclinical for Cardiovascular disorders (unspecified route)
- 18 Aug 2009 Discontinued - Preclinical for Cardiovascular disorders in Germany (unspecified route)
- 04 Apr 2005 Genetronics Biomedical Corporation is now called Inovio Biomedical Corporation